Copyright
©The Author(s) 2023.
World J Gastrointest Surg. Nov 27, 2023; 15(11): 2596-2618
Published online Nov 27, 2023. doi: 10.4240/wjgs.v15.i11.2596
Published online Nov 27, 2023. doi: 10.4240/wjgs.v15.i11.2596
Ref. | Intervention type | Intervention protocol1 | Control protocol | Follow up period2 | ||||||||
Pre-operative regime | Total BCAA received (g)/d | Duration | Post-operative regime | Total BCAA received (g)/d | Duration | Intervention | Control | |||||
Mean | Range | Mean | Range | |||||||||
Ardito et al[45], 2020 | Preoperative, postoperative | BCAA 500 mg 2 tablets TDS with personalised diet (ERAS) | 3 | 2/52 | BCAA 500 mg 2 tablets TDS (ERAS) | 3 | 1/12 | Normal usual diet (ERAS) | NR | NR | NR | NR |
Beppu et al[38], 2015 | Preoperative, postoperative | Livact 4.15 g BD | 8 | 6/12 | NIL | NIL | NIL | Normal usual diet | NR | NR | NR | NR |
Fan et al[43], 1994 | Preoperative, postoperative | BCAA 1.5 g/kg | Weight dependent | 1/52 | BCAA 1.5 g/kg | Weight dependent | 1/52 | Normal usual diet | NR | NR | NR | NR |
Hachiya et al[39], 2020 | Postoperative | NIL | NIL | NIL | Livact 4 g TDS | 12 | 4 yr | Normal usual diet | 21.8 | 1.2-48 | NR | NR |
Ichikawa et al[40], 2013 | Preoperative, postoperative | Livact 4.74 g TDS | 12 | 2/52 | Livact 4.74 g TDS | 12 | ≥ 6/12 | Normal usual diet | 39.5 mo | 7-48 mo | 36.0 mo | 6-50 mo |
Ishikawa et al[30], 2010 | Preoperative, postoperative | Aminoleban EN 50 g BD | 11.123 | 2/52 | Aminoleban EN 50 g BD | 11.123 | 1/52 | Normal usual diet | NR | NR | NR | NR |
Kikuchi et al[41], 2016 | Preoperative, postoperative | Livact 4.74 g TDS | 12 | 1/12 | Livact 4.74 g TDS | 12 | 1 yr | Normal usual diet (35-40 kcal/kg/d) + 4.74 g Livact TDS × 1 yr post-operatively | NR | NR | NR | NR |
Kobayashi et al[36], 2019 | Preoperative, postoperative | Aminoleban EN 50 g ON | 5.5615 | 2/52 | Aminoleban EN ON | 5.5615 | 12/52 | Normal usual diet | NR | NR | NR | NR |
Krapf et al[44], 2021 | Postoperative | NIL | NIL | NIL | High BCAA diet | NA | 2/52 | Normal usual diet (standard isocaloric meal plan) | NR | NR | NR | NR |
Meng et al[31], 1999 | Postoperative | NIL | NIL | NIL | Aminoleban EN TDS with 40 g protein/d + 6300 kJ/d | NA | 12/52 | Normal usual diet (80 g protein/d + 6300 kJ/d) | 511.6d | 6-982 d | 512.7d | 48-983 d |
Nagasue et al[32], 1997 | Postoperative | NIL | NIL | 2/52 | Aminoleban EN 50 g BD | 11.123 | ≥ 1 yr | Normal usual diet | 35.8 mo (17.9) | NR | 36.0 mo (17.7) | NR |
Okabayashi et al[35], 2008 | Preoperative | Aminoleban EN 50 g BD | 11.123 | 2/52 | NIL | NIL | NIL | Normal usual diet | 16.3 mo | 2-47 mo | 23.3 mo | 2-84 mo |
Okabayashi et al[33], 2010 | Preoperative | Aminoleban EN 50 g BD | 11.123 | 2/52 | NIL | NIL | NIL | Normal usual diet | NR | NR | NR | NR |
Okabayashi et al[34], 2011 | Preoperative, postoperative | Aminoleban EN 50 g BD | 11.123 | 2/52 | Aminoleban EN 50 g BD | 11.123 | ≥ 6/12 | Normal usual diet | NR | NR | NR | NR |
Shirabe et al[37], 2011 | Preoperative | Regime 1: Livact 3 packets OD Regime 2: Aminoleban EN 50 g 1 to 3 packets | Regime 1: 12Regime 2: 5.5615-16.6845 | > 1/12 | NIL | NIL | NIL | Normal usual diet | NR | NR | NR | NR |
Togo et al[42], 2005 | Post-operative | NIL | NIL | NIL | Livact 4.74 g TDS | 12 | 1 yr | Normal usual diet | NR | NR | NR | NR |
- Citation: Yap KY, Chi H, Ng S, Ng DH, Shelat VG. Effect of perioperative branched chain amino acids supplementation in liver cancer patients undergoing surgical intervention: A systematic review. World J Gastrointest Surg 2023; 15(11): 2596-2618
- URL: https://www.wjgnet.com/1948-9366/full/v15/i11/2596.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v15.i11.2596